Abstract
Mucopolysaccharidoses (MPS) are lysosomal storage diseases caused by defects in catabolism of glycosaminoglycans. MPS I, II, III and VII are associated with lysosomal accumulation of heparan sulphate and manifest with neurological deterioration. Most of these neurological MPS currently lack effective treatments. Here, we report that, compared to controls, neuraminidase 1 (NEU1) activity is drastically reduced in brain tissues of neurological MPS patients and in mouse models of MPS I, II, IIIA, IIIB and IIIC, but not of other neurological lysosomal disorders not presenting with heparan sulphate storage. We further show that accumulated heparan sulphate disrupts the lysosomal multienzyme complex of NEU1 with cathepsin A (CTSA), β-galactosidase (GLB1) and glucosamine-6-sulfate sulfatase (GALNS) necessary to maintain enzyme activity, and that NEU1 deficiency is linked to partial deficiencies of GLB1 and GALNS in cortical tissues and iPSC-derived cortical neurons of neurological MPS patients. Increased sialylation of N-linked glycans in brain samples of human MPS III patients and MPS IIIC mice implicated insufficient processing of brain N-linked sialylated glycans, except for polysialic acid, which was reduced in the brains of MPS IIIC mice. Correction of NEU1 activity in MPS IIIC mice by lentiviral gene transfer ameliorated previously identified hallmarks of the disease, including memory impairment, behavioural traits, and reduced levels of the excitatory synapse markers VGLUT1 and PSD95. Overexpression of NEU1 also restored levels of VGLUT1-/PSD95-positive puncta in cortical neurons derived from iPSC of an MPS IIIA patient. Together, our data demonstrate that heparan sulphate-induced secondary NEU1 deficiency and aberrant sialylation of glycoproteins implicated in synaptogenesis, memory, and behaviour constitute a novel pathological pathway in neurological MPS spectrum crucially contributing to CNS pathology.
Competing Interest Statement
A.V.P. is a shareholder and received honoraria and research contracts from Phoenix Nest Inc involved in development of therapies for MPS IIID and IIIC. AVP, CWC, and TG are inventors on patents related to human neuraminidase inhibitors. Other authors declare that no competing interests exist.
Abbreviations
- BMDM
- bone marrow derived macrophage
- CNS
- central nervous system
- CPC
- cetylpyridinium chloride
- CTSA
- cathepsin A
- GAG
- glycosaminoglycan
- GALNS
- glucosamine-6-suphate sulphatase
- GLB1
- lysosomal β-galactosidase
- HGSNAT
- acetyl-CoA:alpha-glucosaminide N-acetyltransferase
- HS
- heparan sulphate
- iPSC
- induced pluripotent stem cell
- KO
- knockout
- LMC
- lysosomal multienzyme complex
- LSD
- lysosomal storage disease
- MALDI-TOF
- matrix-assisted laser desorption/ionization – time of flight
- MLD
- metachromatic leukodystrophy
- ML IV
- mucolipidosis IV
- MPS
- mucopolysaccharidosis
- NEU1
- neuraminidase 1
- NPC
- neural progenitor cells
- NPC1
- Niemann-Pick type C1
- PolySia
- polysialic acid
- PolySia-NCAM
- polysialylated neural cell adhesion molecule
- WT
- wild type